Emerging novel therapies in overcoming resistance to targeted therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The recent development of small molecule inhibitors and monoclonal antibodies that target cancer-specific oncogenic driver mutations has significantly improved the outcomes of patients with various tumour types including chronic myeloid leukemia, non-small cell lung cancer and melanoma. Despite high rates of response, most patients will relapse within the first year of targeted therapy due to drug resistance. Although multiple mechanisms of resistance have been defined, these often lead to the re-activation of oncogene-regulated signaling or the activation of compensatory survival cascades. This chapter focusses on emerging therapeutic strategies to overcome and circumvent resistance to targeted therapies, with an emphasis on metastatic melanoma. A variety of therapeutic salvage approaches are being explored, including novel targeted agents, new combination therapies and consideration of drug timing and sequencing. Improved clinical trial design, treatment of earlier stage cancer patients and sensitive real-time monitoring of patient responses and resistance are critical for improving the durability of cancer targeted therapies.
Original languageEnglish
Title of host publicationCurrent applications for overcoming resistance to targeted therapies
EditorsMyron R. Szewczuk, Bessi Qorri, Manpreet Sambi
Place of PublicationSwitzerland
PublisherSpringer, Springer Nature
Chapter8
Pages223-258
Number of pages36
ISBN (Electronic)9783030214777
ISBN (Print)9783030214760
DOIs
Publication statusPublished - 2019

Publication series

NameResistance to Targeted Anti-Cancer Therapeutics
PublisherSpringer
Volume20
ISSN (Print)2196-5501
ISSN (Electronic)2196-551X

Keywords

  • Targeted therapies
  • Melanoma
  • Cancer therapy resistance
  • Receptor tyrosine kinases
  • Immune checkpoint blockade therapy
  • Non-small cell lung cancer

Fingerprint Dive into the research topics of 'Emerging novel therapies in overcoming resistance to targeted therapy'. Together they form a unique fingerprint.

  • Cite this

    Pinho, A. V., Lee, J. H., & Rizos, H. (2019). Emerging novel therapies in overcoming resistance to targeted therapy. In M. R. Szewczuk, B. Qorri, & M. Sambi (Eds.), Current applications for overcoming resistance to targeted therapies (pp. 223-258). (Resistance to Targeted Anti-Cancer Therapeutics; Vol. 20). Switzerland: Springer, Springer Nature. https://doi.org/10.1007/978-3-030-21477-7_8